Peripheral COMT inhibition prevents levodopa associated homocysteine increase. Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm] Journal article | | Title | Peripheral COMT inhibition prevents levodopa associated homocysteine increase. | | Author(s) | Müller T, Muhlack S | | Institution | Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstr. 1, 13088, Berlin, Germany, th.mueller@alexius.de. | | Source | J Neural Transm 2009 Aug 6. | | Abstract | Chronic levodopa (LD)/dopadecarboxylase inhibitor (DDI) increases homocysteine generation as side reaction of O-methylation. Aim was to investigate the impact of the peripheral COMT inhibitor entacapone (EN) on plasma concentrations of homocysteine, LD and 3-O-methyl-dopa (3-OMD). Patients with Parkinson's disease (PD) received on two consecutive days in a standardised fashion one single dose of 200 mg retarded release LD/carbidopa (CD) or of 150 mg LD/CD/EN, since both were shown to have simultaneous pharmacokinetic LD behaviour. Homocysteine increased after retarded release LD/CD application, but not following LD/CD/EN intake. Homocysteine was lower during the LD/CD/EN condition 80 min after baseline when compared with its levels after LD/CD administration. LD levels simultaneously rose on both days. 3-OMD concentrations did not change. Acute LD/CD application caused a rise of homocysteine levels, which was prevented by LD/CD/EN intake. Therefore, peripheral COMT inhibition may have a beneficial effect on putative, controversially debated components of homocysteine-related progression of PD. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19657587 |
|
|
| |
Advertise on this site.
| | |
|
